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Objective: This EAS Consensus Panel critically appraised evidence relevant to the beneﬁt to risk rela-
tionship of functional foods with added plant sterols and/or plant stanols, as components of a healthy
lifestyle, to reduce plasma low-density lipoprotein-cholesterol (LDL-C) levels, and thereby lower car-
diovascular risk.
Methods and results: Plant sterols/stanols (when taken at 2 g/day) cause signiﬁcant inhibition of
cholesterol absorption and lower LDL-C levels by between 8 and 10%. The relative proportions of
cholesterol versus sterol/stanol levels are similar in both plasma and tissue, with levels of sterols/stanols
being 500-/10,000-fold lower than those of cholesterol, suggesting they are handled similarly to
cholesterol in most cells. Despite possible atherogenicity of marked elevations in circulating levels of
plant sterols/stanols, protective effects have been observed in some animal models of atherosclerosis.
Higher plasma levels of plant sterols/stanols associated with intakes of 2 g/day in man have not been
linked to adverse effects on health in long-term human studies. Importantly, at this dose, plant sterol/
stanol-mediated LDL-C lowering is additive to that of statins in dyslipidaemic subjects, equivalent to
doubling the dose of statin. The reported 6e9% lowering of plasma triglyceride by 2 g/day in hyper-
triglyceridaemic patients warrants further evaluation.
Conclusion: Based on LDL-C lowering and the absence of adverse signals, this EAS Consensus Panel
concludes that functional foods with plant sterols/stanols may be considered 1) in individuals with high
cholesterol levels at intermediate or low global cardiovascular risk who do not qualify for pharmaco-
therapy, 2) as an adjunct to pharmacologic therapy in high and very high risk patients who fail to achieve
LDL-C targets on statins or are statin- intolerant, 3) and in adults and children (>6 years) with familial
hypercholesterolaemia, in line with current guidance. However, it must be acknowledged that there are
no randomised, controlled clinical trial data with hard end-points to establish clinical beneﬁt from the
use of plant sterols or plant stanols.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Contents
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H. Gylling et al. / Atherosclerosis 232 (2014) 346e3603481. Introduction and rationale humans, inhibition of cholesterol absorption by ezetimibe results in
lowering of plasma LDL-C levels because of increased fractionalFig. 1. Scheme illustrating the potential impact of cholesterol absorption from the
small intestine on plasma levels of chylomicron remnants and LDL, with detrimental
effects on the vascular wall. Cholesterol (Chol, C) entering the intestinal lumen pri-
marily from the bile and the diet is absorbed to varying degrees and packaged in
chylomicrons (CM-C) for transport via the lymph into the circulation. Therein, hy-
drolysis of much of the triacylglycerol present in the nascent CM results in the for-
mation of cholesterol-rich remnant particles (CMr-C) that are ordinarily rapidly cleared
from the circulation by the liver. Delivery of excess intestinal cholesterol to the liver
can result in suppression of low density lipoprotein-receptor (LDL-R) activity and
endogenous cholesterol synthesis, or acceleration of hepatic very low density
lipoprotein-cholesterol (VLDL-C) secretion, or both. Such events will potentially raise
plasma LDL-cholesterol (LDL-C) concentration. If hepatic clearance of CMr is delayed,
then these particles may contribute directly to plaque formation. Together, these
various pathways illustrate how agents that limit cholesterol absorption may elicit
favourable changes in atherogenic plasma lipoproteins that culminate in attenuating
plaque formation.The on-going pandemic of obesity, metabolic syndrome and
diabetes is directly associated with an ever-increasing worldwide
incidence of premature atherosclerosis and cardiovascular disease
(CVD). Indeed, the European Union budget for CVD is currently
estimated at V196 billion a year, with about one-half of this
attributed to direct healthcare costs [1]. However, limiting the
expenditure for CVD to the healthcare systems of the European
Union grossly underestimates its true cost. Most public health ex-
penses are linked to treatment, a notion which strongly argues for
urgent investment in CVD prevention to improve health in Euro-
pean populations and to stem the socioeconomic consequences.
Recent studies of the relationship of lifetime risk of CVD to risk
factor burden clearly indicate that individuals with an optimal risk
factor proﬁle, (including well-controlled blood pressure and
cholesterol, non-smoking and non-diabetic), display substantially
lower risk of CV events over their lifetime than those with two or
more of these major risk factors [2]. Ranking of nine CV risk factors
in the INTERHEART cross-sectional study in 52 countries revealed
that dyslipidaemia alone accounted for most of the population-
attributable risk for myocardial infarction; here, dyslipidaemia
was deﬁned as an excess of cholesterol transported in atherogenic
apolipoprotein (apo)B-containing lipoproteins (among which low-
density lipoproteins [LDL] predominate), relative to that in non-
atherogenic apoA-I-containing, high-density lipoproteins (HDL)
[3].
Robust data attest to the causal role of LDL-cholesterol (LDL-C)
in coronary atherosclerosis. Reductions in LDL-C levels achieved by
treatment with diet, statins or bile acid sequestrants, or by ileal
bypass surgery, in prospective clinical trials of 3 or more years
duration, have been demonstrated in meta-regression analyses to
signiﬁcantly reduce CV morbidity and mortality [4,5].
As atherosclerosis is a chronic, progressive disease typically
initiated during the ﬁrst three decades of life, it follows that
lowering LDL-C early may substantially delay or even prevent the
onset of atherosclerosis, particularly in the coronary circulation.
Indeed, evidence that prolonged exposure to low plasma LDL-C
levels is associated with markedly greater reduction in CV risk
compared with current strategies aimed at lowering LDL-C in
middle age, has been provided by a meta-analysis of Mendelian
randomisation studies, involving polymorphisms in six distinct
genes of cholesterol metabolism [6].
These ﬁndings prompt a key question: How can LDL-C be
maintained at low levels throughout life without imposing addi-
tional burden on the healthcare system? Clearly, lifestyle, which
encompasses dietary habits, must be seriously considered, partic-
ularly as extensive nutritional and behavioural changes may lower
LDL-C levels by up to 20% [7].
The liver is the principal regulator of circulating LDL-C levels.
Not only is it the site of formation of very low-density lipoproteins
(VLDL), the precursors of most LDL particles in the circulation, but it
is also the site of most receptor-mediated clearance of LDL [8]. Both
the liver and intestine are central to body cholesterol homeostasis.
Indeed, after lipolysis-mediated removal of dietary triglycerides
from chylomicrons, the liver rapidly clears circulating chylomicron
remnants, which carry cholesterol that was absorbed in the small
intestine [9]. The resultant increase in hepatic cholesterol stimu-
lates VLDL secretion and hence LDL formation, and down-regulates
hepatic LDL receptor activity. Such events potentially lead to ele-
vations in plasma LDL-C levels. Both chylomicron remants and VLDL
remnants, in addition to LDL, can deliver cholesterol to the artery
wall, initiating or exacerbating atherosclerosis. When cholesterol
absorption in the small intestinewas inhibited by ezetimibe in apoE
deﬁcient mice, atherosclerosis was dramatically reduced [10]. Inremoval of LDL from the circulation, consistent with less dietary
cholesterol arriving at the liver via chylomicron remnants with
subsequent upregulation of LDL receptors [11,12]. Inhibition of
cholesterol absorption by ezetimibe was also associated with
reduced chylomicron secretion into plasma as determined by
reduced production of apoB48 (Fig. 1) [12].
Thus it follows that the cholesterol absorption pathway repre-
sents an attractive target in themanagement of dyslipidaemia, with
a speciﬁc focus on both reducing the cholesterol content of chylo-
micron and VLDL remnants and lowering LDL-C levels. This
pathway presents clinical opportunities for dietary supplementa-
tion with agents that attenuate intestinal cholesterol absorption,
among which plant sterols and plant stanols are prominent.
The European Atherosclerosis Society (EAS) convened an inter-
national Consensus Panel of basic scientists and clinical in-
vestigators with expertise in cholesterol metabolism, plant sterol
and plant stanol biology, and CVD. Our goals were (i) to critically
appraise state-of-the-art knowledge pertaining to the potential of
plant sterols and plant stanols (hereafter referred to as plant ste-
rols/stanols) for lowering LDL-C, with a view to preventing pre-
mature atherosclerosis and CVD, and (ii) to propose
recommendations for optimal integration of foods with added
plant sterols/stanols, as part of a healthy lifestyle, for attenuation of
CV risk. These recommendations can provide guidance and support
for clinicians and health professionals in the prevention of CVD
across the spectrum of CV risk.2. Biology and mode of action of plant sterols/stanols
2.1. Origins
Plant sterols/stanols are bioactive components with similar
functions as that of cholesterol in mammals. Plant sterols are ste-
roid alkaloids which differ from cholesterol in the structure of their
Table 1
Plant sterol and plant stanol contents in different foods. Data are given as mg/100 g
(dry weight, either range or mean value).
Food item Plant sterols Plant stanols
Vegetable oils
Corn oil 686e952 23e33
Rapeseed oil (canola oil) 250e767 2e12
Soybean oil 221e328 7
Sunﬂower oil 263e376 4
Olive oil 144e193 0.3e4
Palm oil 60e78 Traces
Cereals
Corn 66e178 e
Rye 71e113 12e22
Wheat 45e83 17
Barley 80 2
Millet 77 e
Rice 72 3
Oats 35e61 1
Nuts
Peanuts 320 e
Almond 143 e
Vegetables
Broccoli 39 2
Cauliﬂower 18e40 Traces
Carrot 12e16 Traces
Lettuce 9e17 0.5
Potato 7 0.6
Tomato 7 1
Fruits and berries
Avocado 75 0.5
Passion fruit 44 Not detected
Raspberry 27 0.2
Orange 24 Not detected
Apple 12e18 0.8
Banana 12e16 Not detected
e, Not reported.
Source: Adapted from Piironen V & Lampi AM (2004) [15].
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sterols (Fig. 2).
Themain food sources of plant sterols are vegetable oils, spreads
and margarines, breads, cereals, and vegetables (Table 1); these
contribute 50e80% of the daily plant sterol intake, with fruits
adding a further 12% [13e15]. In the typical Western diet, the mean
daily intake of plant sterols is about 300 mg [13,14], but can be as
high as 600 mg in vegetarians [16]. The most abundant are sitos-
terol and campesterol, which contribute 60% and 20%, respectively,
of plant sterol intake [13,14]. By comparison, the amounts of plant
stanols in the diet are much lower, with only about 17e24 mg per
day (predominantly sitostanol and campestanol) [14]. Cereals,
especially wheat and rye, are the richest source of plant stanols.
2.2. Transport and circulating levels
These dietary components undergo low fractional absorption in
the intestine, of the order of 0.5e2% for plant sterols and 0.04e0.2%
for plant stanols [17]. As a result of low absorption and efﬁcient
excretion into bile after uptake by the liver, circulating levels are
low, varying from 7 to 24 mmol/L (0.3e1.0 mg/dL) for plant sterols,
and from 0.05 to 0.3 mmol/L (0.002e0.012 mg/dL) for plant stanols
[18]; these levels are of the order of 500-fold and 10,000-fold lower,
respectively, than those of cholesterol.
Long-term consumption of foods with added plant sterols
(mean intake  standard deviation [SD] 1.1  0.6 g/day) increases
their circulating levels (from 19 to 30 mmol/L [0.8e1.2 mg/dL] with
plant sterol consumption), which overlap those within the normal
range [19]. For foods with added plant stanols (mean intake
0.6  0.4 g/day), increases in circulating levels of plant stanols
(from 0.3 to 0.7 mmol/L [0.012e0.028 mg/dL] with plant stanol
consumption), and a decrease in circulating plant sterols (from 16
to 23%), were observed [19]. The quantitative distribution of plant
sterols/stanols across the major lipoprotein classes is similar to that
of cholesterol, and thus they circulate primarily in LDL particles
(65e70%).Fig. 2. Chemical structure of plant stanols and plant sterols.
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ABCG8) play a crucial role in controlling the absorption of plant
sterols/stanols by secreting absorbed molecules back into the in-
testinal lumen [20,21]. In phytosterolaemia, severe loss of function
mutations in genes coding for the ABCG5/ABCG8 transporters
result in dramatic elevation in plasma plant sterol/stanol levels,
which are more than 50-fold higher than those in normal in-
dividuals after consumption of plant sterols, and many of these
individuals develop premature atherosclerosis (Box 1) [20e22].
Further consideration of this rare genetic disease is, however,
beyond the scope of the present paper, which is focussed on plant
sterol/stanol consumption as part of a healthy diet for prevention of
CVD.
2.3. Tissue levels
There are limited data available for tissue levels in subjects
receiving foods with added plant sterols/stanols. In healthy human
subjects, plant sterols/stanols are taken up into tissues in similar
proportions relative to cholesterol, and the ratio of cholesterol to
plant sterols/stanols, which displays a wide range (0.001e
0.01  104), is similar to or less than that in plasma, consistent
with the absence of preferential accumulation or retention in tis-
sues (see Supplementary Table 1). Similar ﬁndings have been re-
ported for cerebrospinal ﬂuid and brain tissue in healthy control
subjects, and also in phytosterolaemia [23,24]. In healthy volun-
teers, data on tissue plant sterol/stanol levels are available for the
carotid artery wall and for non-stenotic and stenotic aortic valve
cusps [25e28]. In these tissues, cholesterol content is 20 mg/mg of
tissue, while total plant sterol and plant stanol concentrations are
w0.04 mg/mg andw0.001 mg/mg of tissue, respectively. Plant sterol
concentrations vary widely between tissues (see Supplementary
Table 1) [25e30].Box 1
Phytosterolaemia
 Phytosterolaemia (previously referred to as sitoster-
olaemia) is due to rare, loss of function mutations in
genes coding for the ATP-binding cassette transporters
G5 and G8 (ABCG5/ABCG8), and is characterised by very
high serum levels of plant sterols (up to 1.3 mmol/L or
50 mg/dL) and plant stanols (0.2 mmol/L or 8 mg/dL) [18].
 Major clinical manifestations may include premature
atherosclerosis although this complication is variable;
there are a number of patients with phytosterolaemia who
do not have evidence of atherosclerosis (D. Lu¨tjohann,
personal communication; E. Bruckert, privileged commu-
nication). The presence of premature atherosclerosis ap-
pears to depend on whether there is co-existing severe
hypercholesterolaemia. Other complications of phytos-
terolaemia include episodes of haemolysis, and xantho-
mas. Moreover, it is noteworthy that recent findings in 4
adult phytosterolaemic patients have not detected any
significant degree of atherosclerosis (E. Bruckert, privi-
leged communication).
 Plant sterols have been shown to accumulate in athero-
sclerotic lesions of phytosterolaemic subjects in the same
ratio as present in serum. However, the phytosterol/
cholesterol ratio is higher in phytosterolaemia than in
normal subjects in plasma and in tissues.
 The potential relevance of markedly elevated amounts of
plasma and tissue plant sterols and plant stanols to tissue
deposition and the atherosclerotic process remains
indeterminate.During consumption of plant sterol-enriched foods, there was a
5-fold elevation in campesterol in stenotic aortic valve cusps [28].
However, in another study, the concentration of plant stanols in the
arterial wall was not modiﬁed during consumption of foods
enriched with plant stanols [27]. Clearly, there is a need for large,
long-term clinical studies to exclude the possibility that con-
sumption of dietary plant sterols/stanols might result in accumu-
lation in arterial tissues, and evaluation of these agents as
modulators of plaque formation or regression is equally of interest.
Such studies present multiple methodological challenges, not least
of which is access to plaque tissue for analysis of sterol composi-
tion, and for determination of the expression proﬁle of key genes of
cholesterol and plant sterol metabolism.2.4. Markers of intestinal cholesterol absorption and synthesis
Serum cholesterol precursors and plant sterols, especially when
expressed as ratios relative to cholesterol, can constitute markers of
the rates of synthesis and absorption of cholesterol in non-
dyslipidaemic subjects, as well as in several clinical conditions
including primary and familial hypercholesterolaemia (FH), obesity
and type 2 diabetes, and during some interventions including plant
stanol consumption [31,32]. Overall, such markers have good val-
idity, but there are exceptions (see Supplementary Appendix) [31e
33], and full validation in multiple conditions is essential. More-
over, there are a number of methodological issues relating to
standardisation of these markers. An on-going survey is investi-
gating the degree of variability in sterol/stanol analytical data
across different laboratories (see Supplementary Appendix).2.5. Intestinal handling of cholesterol and non-cholesterol sterols:
mechanism by which plant sterols/stanols added to the diet inhibit
the absorption of cholesterol
The handling of sterols and stanols entering the intestinal lumen
from the diet and bile is essentially a triphasic process (Fig. 3) [34e
37]. The ﬁrst phase is largely physicochemical in nature, occurs
intraluminally, and culminates in the incorporation of cholesterol
and other sterols and stanols into mixed micelles that serve as
vehicles to carry these poorly water-soluble substances up to the
surface of the brush border membrane on the enterocyte. This
solubilisation step is essential for the subsequent entry of any type
of sterol into the absorptive cell, from where it may potentially
reach the circulation.
The second major phase is the uptake of cholesterol and other
sterols or stanols into the enterocyte, a process that is facilitated by
a plasma membrane-localised, general sterol transporter protein,
Niemann-Pick C1-Like1 (NPC1L1). Within the absorptive cells,
sterols undergo different fates, depending mainly on their chemical
structure. Collectively, these events within the enterocyte broadly
constitute the third major phase of intestinal handling. The
bulk of the cholesterol is esteriﬁed by acyl CoA: cholesterol
acyltransferase-2 (ACAT2) and incorporated into nascent chylomi-
crons, which initially enter the lymph before joining the circulation
via the thoracic duct [38,39]. The absolute content of plant sterols/
stanols in chylomicrons is markedly lower than that of cholesterol,
with up to 50% in esteriﬁed form [39]. Importantly, the bulk of plant
sterols/stanols is pumped back into the gut lumen via the ABCG5/
ABCG8 transporter, resulting in minimal entry of these plant-
derived molecules into the circulation [34,40,41]. Finally, foods
with added gram quantities of plant sterols/stanols cause a signif-
icant inhibition of cholesterol absorption, most likely through
disruption of the intraluminal solubilisation step [37], although
other possible mechanistic explanations have been proposed [42].
Fig. 3. Schematic summarising the three main steps (indicated by the numbers in red circles) involved in the intestinal handling of cholesterol and non-cholesterol sterols. In the
ﬁrst step within the intestinal lumen, sterols are incorporated into mixed micelles (1). At the brush border membrane, sterols are released from the micelles and transported into
the cell via the Niemann-Pick C1-Like1 transporter (NPC1L1) (2). Once internalised, these sterols can be handled in different ways (3). For the bulk of the internalised non-
cholesterol sterols, efﬂux back into the lumen occurs via ABCG5/ABCG8 (ATP binding cassette transporters G5 and G8). In contrast, a signiﬁcant proportion of the internalised
cholesterol undergoes esteriﬁcation via ACAT2 (acyl CoA-cholesterol acyltransferase-2). The esteriﬁed cholesterol, along with much smaller quantities of esteriﬁed non-cholesterol
sterols, are incorporated into nascent chylomicrons which enter the lymphatic system and ultimately the circulation. Dietary plant sterol or stanol supplementation is believed to
inhibit the absorption of cholesterol most likely through disruption of the intraluminal solubilisation step [37]. Abbreviations: apo apolipoprotein; C cholesterol; CE cholesteryl
ester; FA fatty acid, MTP microsomal triglyceride transfer protein; TG triglyceride.
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regulating circulating levels of plant sterols [20,21]. In the KORA
study, common variants of rs41360247 and rs4245791 in the ABCG8
gene accounted for 8% of the variance in circulating levels of plant
sterols [43]. The relationships of these and other variants in high
linkage disequilibrium with circulating plant sterol levels have
been conﬁrmed in the CARLA, LURIC, and YFS cohorts [43,44].Box 2
Types of foods with added plant sterols or plant stanols
Low-fat spread/margarine
Yoghurt drinks
Dairy-free drinks
Low- or reduced-fat milk
Soft cheese
Orange juice
Muesli
Bread
Biscuits3. Lipid modifying effects of plant sterols/stanols
3.1. LDL cholesterol lowering
Epidemiological studies in the UK (n ¼ 22,256), Sweden
(n ¼ 77,652) and China (n ¼ 3940) observed that naturally-
occurring dietary plant sterol intake is inversely related to plasma
total- and LDL-C levels [45e47]. However, in a well-controlled
study in healthy subjects, low (126 mg plant sterols/2000 kilocal-
ories) or high intake of plant sterols (449 mg plant sterols/2000
kilocalories) did not affect plasma LDL-C concentrations in spite of
modulating cholesterol metabolism [48]. Furthermore, even at the
highest levels of dietary intake, plant sterols/stanols occurring
naturally in the diet have a modest hypocholesterolaemic effect. On
the other hand, when natural plant sterols were omitted from the
diet, serum LDL-C concentrations increased [49].
In contrast to the minimal effects of variation in consumption of
naturally-occurring plant sterols/stanols in the diet, early studies
such as that by Farquhar et al. (1956) demonstrated that beta-
sitosterol supplementation lowered both total serum cholesterol
and LDL-C (as beta-lipoprotein lipid) in young men with athero-
sclerotic heart disease [50]. Subsequently, Miettinen et al. (1995)
demonstrated for the ﬁrst time that foods (such as margarine, see
Box 2) enriched with sitostanol ester lowered both total serum
cholesterol and LDL-C in mildly hypercholesterolaemic subjects
[51].
Subsequent data show consistent support for the LDL-C
lowering effects of foods with added plant sterols/stanols [52e54]. In the most recent meta-analysis, consumption of foods with
added plant sterols/stanols (2 g/day) lowered LDL-C to a similar
extent (8.2% and 9.3%, respectively) [54]. Regrettably, there is a
paucity of data relating to the potential of higher plant sterol/stanol
doses to further lower LDL-C levels, and thus CV risk [6,54,55]. It has
been suggested that maximal LDL-C lowering may be greater with
plant stanols (up to 16%) and plant stanol esters (17%), but this
conclusion relies on limited studies using doses of 4e9 g/day, none
of which involved direct head-to-head comparisons with plant
sterols. Whether there is a position for plant sterol and/or plant
stanol intakes to be raised higher than those currently recom-
mended (2e3 g/day) in prevention strategies for the general pop-
ulation remains open. The fact that there is consistent, robust
evidence indicating that lowering of LDL-C by different mecha-
nisms (statins, diet, partial ileal bypass, bile acid sequestrants) re-
sults in reduction in CV risk, underlies the rationale for inclusion of
plant sterols/stanols in international clinical guidelines for the
management of dyslipidaemia [5,56]. In this context, it must be
recognised that the use of functional foods enriched with plant
sterols/stanols is currently not advised for children under 6 years.
There is, however, a substantial database showing consistent LDL-C
lowering efﬁcacy in children. In controlled clinical trials in children
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mented with plant sterols/stanols (1.5e3 g/day) resulted in
consistent LDL-C reduction (by 5e15%) in normolipaemic children
(n ¼ 98), and equally in children with FH (n ¼ 224; by 9e19%) (see
Supplementary Table 2) [57e66]. Themagnitude of such reductions
is comparable to that observed in adults. On this basis, the Panel
proposes that dietary supplementation with plant sterols/stanols
may be considered in children (from the age of 6 years) with FH
who require lipid lowering treatment as an adjunct to lifestyle
advice and potential pharmacotherapy, although long term safety
studies are clearly needed.
3.2. Additional effects on the plasma lipid proﬁle
Most studies with plant sterols/stanols were conducted in in-
dividuals with isolated hypercholesterolaemia. The available data
suggest that triglyceride levels are reduced by 6e20% at intakes of
1.5e2 g/day of plant sterol/stanol, with essentially no effect on
HDL-C [67e69]. Pooled analyses showed a modest reduction in
plasma triglycerides of 6% and 4% for recommended intakes of plant
sterols (1.6e2.5 g/day) or plant stanols (2 g/day), respectively
[69,70]. Indeed, evidence suggests a relationship between baseline
triglyceride levels and the magnitude of this effect, with 9%
reduction when baseline triglycerides were 1.9 mmol/L (170 mg/
dL), but no effect at baseline levels of 1.0 mmol/L (90mg/dL) [69]. In
subjects with metabolic syndrome and moderate hyper-
triglyceridaemia, plant stanols lowered hepatic production of both
large (>60 nm) and medium size (35e60 nm) VLDL particles [67].
Other studies documented a reduction in small, dense LDL particles
in patients with type 2 diabetes or metabolic syndrome after con-
sumption of plant stanols/sterols [68,71]. Based on one study, it
appears that plant sterols/stanols do not inﬂuence lipoprotein(a)
levels [72].
Finally, it is of considerable interest that LDL-C reduction, sub-
sequent to consumption of a plant stanol ester-enriched diet in a
population of metabolic syndrome subjects, was without effect on
plasma levels of proprotein convertase subtilisin/kexin type 9
(PCSK9) (J Plat, unpublished data), a potential contrast to the
elevation in PCSK9 levels induced upon statin-mediated LDL-C
lowering [73].
Future studies of the potential effects of foods with added plant
sterols/stanols in attenuating the atherogenicity of the postprandial
period in well-phenotyped cohorts of subjects with metabolic
syndrome or type 2 diabetes would be of special interest. Such
investigations should focus on normalisation of both the qualitative
and quantitative features of atherogenic triglyceride-rich lipopro-
teins and their remnants during this phase.
4. Effects on atherosclerosis
4.1. Studies in animal and cell-based models
Because plant sterols/stanols effectively reduce plasma LDL-C
concentrations, their use could constitute a potential protective
strategy against the initiation and progression of atherosclerosis.
Most of the available supportive data relate to studies in animal-
and cell-based models, however, these have inherent limitations.
Thus, investigations in animal models have been of short duration,
while very high (pharmacological) doses have been typically
applied in both animal and cell models, thereby highlighting the
need for cautious interpretation of the experimental ﬁndings.
4.1.1. Animal models
To date, more than 30 studies have investigated the effect
of plant sterol/stanol supplementation on experimentalatherosclerosis in various animal models (see Supplementary
Table 3 and reviewed by Kritchevsky and Chen [2005]) [74]. In
genetically-modiﬁed mouse models of atherosclerosis, protective
effects were observed despite increases (up to 10-fold) in plasma
plant sterol/stanol concentrations [28,75,76]. Such effects included
reduction in arterial lipid accumulation, and inhibition of lesion
formation and progression. Moreover, regression of existing lesions
correlated with the cholesterol-lowering action of plant sterols/
stanols.
4.1.2. Cell-based models
4.1.2.1. Cellular metabolism of plant sterols/stanols and potential
impact on cholesterol metabolism. The proportions of plant sterols/
stanols relative to cholesterol found in plasma are maintained in
tissue sterols [24,26], suggesting that they are handled similarly to
cholesterol inmost cells. While direct studies of cellular plant sterol
metabolism are relatively limited in scope, they support this view.
For example, the rates of uptake and accumulation of sitosterol and
cholesterol by macrophages are similar [77], and substantial
esteriﬁcation of beta-sitosterol (¼sitosterol) and other plant sterols
can be measured in many tissues and cells [26,78,79]. On the basis
of limited data, efﬂux of sitosterol and sitostanol to HDL from hu-
man macrophages appears to be more efﬁcient than that of
cholesterol [77].
Cholesterol homeostasis is tightly controlled at the transcrip-
tional level via Sterol Regulatory Element-Binding Protein-2 and
liver X receptor (LXR)-dependent regulation, and also by post-
translational control of the turnover of a number of key enzymes,
receptors and transporters. Plant sterols appear to have little or no
impact on these processes. Their ability to activate LXR-dependent
genes is negligible or very low [80e84]. A plant sterol-enriched diet
had no effect on mouse intestinal LXR target gene expression [85].
In future studies, more comprehensive evaluation of the effects of
‘physiological’ concentrations of plant sterols/stanols on the he-
patic and intestinal gene expression proﬁle would be of consider-
able interest.
4.1.2.2. Inﬂuence of plant sterols/stanols on inﬂammatory pathways.
In macrophages, recent studies have shown that lipid accumulation
and inﬂammatory responses are co-ordinated through LXR-
mediated transrepression of inﬂammatory genes by desmosterol,
an intermediate in cholesterol synthesis and an endogenous LXR
ligand [86,87]. Interestingly, as plant sterol/stanol consumption
results in a compensatory increase in endogenous cholesterol
synthesis [31], the corresponding increase in intracellular des-
mosterol concentrations could result in plant sterol/stanol-induced
anti-inﬂammatory effects. Indeed, a number of in vitro studies
indicate that some plant sterols exert anti-inﬂammatory effects on
activated macrophages. However, these studies have signiﬁcant
limitations, as they involved addition of plant sterols and/or stanols
under conditions, which (although seldom directly measured),
almost certainly signiﬁcantly increase the plant sterol:cholesterol
ratio to values well in excess of the normal 1:500 to 1:1000 ratio
that exists in vivo. This is likely evenwhen plant sterols are added at
‘physiological’ concentrations. Future studies must include direct
measurement of the cellular levels of cholesterol and plant sterols
and should aim to mimic those found in vivo.
There are conﬂicting ﬁndings with respect to the effects of
sitosterol and campesterol on production of proinﬂammatory fac-
tors by macrophages [88e92]. Interestingly, sitosterol stimulated
anti-oxidant pathways and inhibited either phorbol ester- or
lipopolysaccharide-stimulated prostaglandin synthesis in mouse
macrophages [93e96]. The potential relevance of these ﬁndings to
the atherosclerotic process is unclear at present, but warrants
further research. In addition to macrophages, substantial evidence
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inﬂammatory dimension of atherosclerosis [97]. Interestingly,
both plant sterols and plant stanols exert immune-modulating
properties, to the extent that the evoked T-helper cell (Th) 1
response, as shown by enhanced production of the Th1 cytokines,
interferon-gamma and interleukin-2, and activation of toll receptor
2, is an essential feature of this response [92].
Thus, in summary and based on the evidence discussed, we
cannot exclude the possibility that accumulation of plant sterols/
stanolsmight occur in vascular cells as a consequence of an increase
in their circulating concentrations (see Box 3).
4.2. Studies in humans
4.2.1. Relationship of plant sterol/stanol consumption and vascular
health
Human studies evaluating the effect of dietary plant sterols/
stanols on measures of arterial structure or function using carotid
intima media thickness, brachial artery size, ﬂow-mediated dila-
tation (FMD), and arterial stiffness have not shown any major,
consistent effects on vascular or endothelial function during short
andmid-term plant sterol or plant stanol intake [64,66,98e103]. All
studies were small and mostly of short duration, and importantly,
several studies were in subjects with low CV risk exhibiting normal
vascular function at baseline. Despite signiﬁcant reductions in LDL-
C levels, no consistent changes in measures of inﬂammation,
oxidative stress or endothelial functionwere observed. In a study of
apparently healthy non-smokers, daily use of plant stanol marga-
rine for 2 years did not improve carotid artery compliance [103],
and in a shorter (3 months) study, failed to impact FMD [98].
Similarly, in two studies in pre-pubertal children with FH, dietary
plant sterol/stanol consumption did not improve endothelial
function despite signiﬁcant LDL-C lowering [64,66].
Recent research has focused on the characteristics of the
microcirculation as markers of early arterial disease [104]. In one
trial [105], intake of foods enriched with plant sterols/stanols
(2.5 g/day) for 85 weeks by statin-treated subjects showed an as-
sociation between the increase in serum campesterol concentra-
tions and changes in both retinal arteriolar and venular diameters.
Retinal venular diameters increased (by 2.3 3.1 mm) and arteriolar
diameter decreased (by 0.7  4.7 mm) in the group receiving added
plant sterols, although these effects did not reach signiﬁcance.
However, the change in cholesterol-standardised campesterol
concentrations correlated positively with the change in venular
diameter independent of changes in LDL-C concentration. Other
studies with endpoints including coagulation [72], plateletBox 3
Implications from studies in animal- and cell-based models of
the impact of plant sterols and plant stanols on atherosclerosis
 The limited available data indicate that most cells handle
(uptake, esterification, export) plant sterols/stanols in a
similar manner as cholesterol.
 In vivo, plant sterols represent w0.1% of total cellular
sterol; however, most in vitro studies have involved the
use of much higher levels of plant sterols.
 Evidence suggests that plant sterols do not affect cellular
cholesterol homeostasis, although further studies are
needed to confirm this.
 Some studies indicate mild anti-inflammatory effects of
plant sterols/stanols, but confirmation is required at
‘physiological’ levels of plant sterols.
 Plant sterols are not toxic at ‘physiological’ concentrations.aggregation measures [106], oxidant stress [107], inﬂammation
[108] or other biomarkers did not demonstrate convincing beneﬁt.
It is possible, however, that the reduction of LDL-C by 10%, as
typically mediated by intake of foods with added plant sterols/
stanols, may not attain the threshold required for impact on these
parameters. Adequately powered, controlled studies of the effects
of plant sterols/stanols on morphological, functional and
biochemical surrogatemarkers of atherosclerosis are needed. Based
on present evidence, there is no indication that dietary supple-
mentation with plant sterols/stanols are associated with either
beneﬁt or harm to vascular function.
4.2.2. Relationship of circulating plant sterols/stanols and CV risk:
Cohort studies
Several observational studies have investigated the association
between circulating plant sterols and atherosclerosis in the general
population. Some early reports found moderately elevated plant
sterol levels to be positively associated with vascular disease
[109,110], although others suggested an inverse or lack of rela-
tionship between circulating plant sterols and CV risk [111e113]. A
recent meta-analysis including 17 studies (n ¼ 11,182) [114],
showed no signiﬁcant associations of circulating campesterol and
sitosterol with vascular disease over a range of circulating plant
sterol concentrations (average concentrations for ﬁrst and third
tertiles, 0.17 and 0.47 mg/dL [4 and 12 mmol/L] for campesterol, and
0.13 and 0.38 mg/dL [3 and 10 mmol/L] for sitosterol). Two studies
showed inverse relationships between plant sterols and CV risk,
one study did not ﬁnd any association, and a further study reported
a positive association between plant sterols and CV risk [115e118].
Since these retrospective/case-control and prospective/cohort
studies do not provide the highest level of evidence in deﬁning
causality, and as placebo-controlled trials with these endpoints are
lacking, Mendelian randomisation studies may be informative.
Moderate elevations of circulating plant sterols, which are associ-
ated with plant sterol-raising variants in the ABCG8 gene, showed a
positive association with prevalent coronary artery disease
[43,119e122]. Such an increase in risk can, however, be entirely
explained by the association of ABCG8 variants with intestinal
cholesterol absorption, as reﬂected by circulating cholestanol
levels, and with LDL-C plasma concentration, rather than circu-
lating levels of plant sterols [44,123e126]. The ABO gene has also
been associated with elevated circulating sterol levels and CV risk
[43]. However, the ABO locus exhibits even greater pleiotropy than
the ABCG5/G8 locus, as it regulates von Willebrand factor, coagu-
lation factor VIII, intercellular adhesion molecule-1, P-selectin, and
E-selectin levels [127e129]. In the largest report to date (n¼ 1242),
circulating levels of plant sterols were lower in the group with
coronary artery disease (CAD), and concentrations of the plant
stanols, campestanol and sitostanol, which are much lower than
those of plant sterols, were not different between the groups with
and without CAD [130]. Thus, the available Mendelian random-
isation studies do not provide a scientiﬁc basis to discourage the
use of plant sterol- or plant stanol-containing functional foods.
A healthy diet is the cornerstone of CVD prevention. In this
respect, it is of critical importance that indisputable evidence
supports the contention that lowering of plasma LDL-C levels
confers clinical beneﬁt, irrespective of mechanism, and that such
mechanisms include dietary intervention [4e7,131e133]. Indeed,
robust data show that there is no qualitative difference between
statin- and non-statin-mediated reduction in LDL-C when
comparing their estimated effects on myocardial infarction or CHD
death on the basis of the Bayes factor [5]. Thus, the regression lines
for all individual diet (n ¼ 5), bile acid sequestrant (n ¼ 3), surgery
(n ¼ 1), and statin (n ¼ 10) trials were similar and consistent with a
one-to-one relationship between LDL-C lowering and reduction in
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discussed above, it is of immediate relevance that consumption of
2 g/day of plant sterols/stanols, as part of a healthy diet, lowers LDL-
C plasma levels by approximately 10% [52e54].
The EAS Consensus Panel on Phytosterols, however, recognises
that there is a lack of randomised data pertaining speciﬁcally to the
impact of foods with added plant sterols/stanols on CVD preven-
tion. Large-scale outcome trials of food products with added plant
sterols/stanols for CVD prevention in the setting of low to inter-
mediate risk are not practically feasible, given the very large
number of subjects (>50,000) required for adequate power (see
Supplementary Appendix 2. Feasibility of an outcomes study for
food products with added plant sterols/stanols). Furthermore,
the beneﬁt of consistent, but relatively small, additional LDL-C
lowering from consumption of foods with added plant sterols/
stanols, as part of a healthy diet, would be difﬁcult to demonstrate
deﬁnitively in a clinical trial of optimally treated patients at high CV
risk, even if 25e30,000 individuals were enrolled. The absence of
randomised, controlled trial data with hard end-points to establish
clinical beneﬁt from the use of plant sterols or plant stanols must be
considered when health professionals choose to advise their use as
supplements to a healthy diet.
5. Safety
In the context of beneﬁt-risk considerations, substantial interest
has focused on the safety aspects of plant sterols/stanols when used
as cholesterol-lowering agents. Given that the level of plant sterol/
stanol intake required for cholesterol lowering ranges from 1 to 3 g/
day, well above typical consumption patterns which rarely exceed
400e600 mg/day, a considerable literature has amassed exploring
possible deleterious effects of prolonged plant sterol/stanol con-
sumption. Indeed, for some individuals zealously consuming mul-
tiple foods with added plant sterols/stanols, it is feasible that
intakes could rise considerably above the 3 g/day level considered
to represent the ceiling at which the dose-response curve for
cholesterol-lowering with plant sterols begins to plateau. However,
evidence from clinical studies and post-launch monitoring in-
dicates that overconsumption of foods with added plant sterols/
stanols is not an issue [19,134].
Speciﬁc areas of concern surrounding plant sterol/stanol con-
sumption include (i) possible negative effects on fat-soluble
vitamin status, and (ii) and cancer risk. Overall, longer-term post-
launch monitoring efforts have failed to answer the question
whether foods with added plant sterols/stanols cause any unex-
pected negative health effects [135,136]. Several longer-term
feeding trials have similarly failed to identify any negative action
of plant sterol/stanol consumption on clinical chemistry, haema-
tology or clinical symptomology [52e54,137,138].
A repeated observation in some, but not all, plant sterol feeding
trials is modest suppression of plasma carotenoid concentrations
(by 10%), especially for the highly lipophilic hydrocarbon caroten-
oids (beta-carotene, alpha-carotene and lycopene) [139,140]. It has
been suggested that this may arise from suppression of intestinal
absorption [141]. Increasing consumption of fruits and vegetables
offsets any decline in fat-soluble vitamin levels induced by plant
sterol/stanol intakes in the range that lowers cholesterol [139].
Considerable controversy has occurred over the past decade
regarding a possible atherogenic role of high circulatory levels of
plant sterols/stanols. Reports are conﬂicting, although the most
recent work seems to indicate that plasma levels of plant sterols
associated with recommended intakes (2 g/day) do not pose a
health risk. Mendelian randomisation studies have claimed to show
that increased circulatory levels of plant sterols increase CVD risk,
but since the ABCG5/G8 polymorphisms examined have pleiotropiceffects, the results of these studies can readily be explained by an
increased cholesterol absorption rate (see above).
Lastly, considerable evidence from animal and cell studies sug-
gests, if anything, a protective role of sitosterol against certain
cancers [142e145]. Thus, there is no increase in cancer risk with
recommended daily intakes of functional foods containing 2e3 g/
day of plant sterols/stanols. In fact, surveillance data associate
reduced risk of certain cancers with plant sterol/stanol intakes
[146,147]. Possible mechanisms based on animal and cell work
suggest direct actions on apoptosis or indirect actions through the
intracellular cholesterol-lowering ability of these agents [145].
Overall, evidence from longer-term monitoring trials, as well as
experimental models, indicates that plant sterols/stanols present a
favourable safety proﬁle, thereby supporting their use in choles-
terol lowering, either alone or adjunctive to pharmacotherapy.
Based on the epidemiology, the genetics, and the wealth of current
clinical trial evidence demonstrating LDL-C lowering with plant
sterols/stanols and lack of signiﬁcant safety concerns, the use of
plant sterols/stanols in treating hypercholesterolaemia can be
encouraged [56]. The question remains how best to optimise their
use in lipid management.
6. Optimising the use of plant sterols/stanols in lipid lowering
6.1. Combination therapy
In addition to a role in primary prevention in the general pop-
ulation, foods with added plant sterols/stanols may provide addi-
tional LDL-C lowering in dyslipidaemic patients at high CV risk
treated with lipid-lowering drugs. Thus, it is important to deﬁne
the lipid-modifying effects of dietary plant sterols/stanols (2e3 g/
day) in combination with pharmacotherapies so as to optimise
their clinical use.
6.1.1. Statins
Statins are inhibitors of the rate-limiting enzyme of cholesterol
biosynthesis, HMG-CoA reductase. As such, their action directly
decreases intracellular levels of cholesterol and its precursors, en-
hances the catabolism of apoB-containing lipoproteins (mainly
LDL) via upregulation of hepatic LDL receptors, and reduces de novo
hepatic (and potentially intestinal) lipoprotein production. Since
plant sterols/stanols act via a distinct mechanism, i.e. by lowering
bioavailability of intestinal cholesterol for entry into the circulation,
it can be speculated that plant sterols/stanols may exert an additive
effect when combinedwith a statin. In clinical studies, dietary plant
sterols/stanols induce an incremental decrease in LDL-C levels of
10e15% when added on top of statin therapy, which is superior to
that (6%) obtained by doubling the statin dose [148e151]. In vivo
studies of LDL-apoB kinetics in patients with type 2 diabetes mel-
litus indicated that the additive effects on LDL-C reduction when
stanols were added to statins resulted from decreased production
of LDL [152]. Thus, the generally accepted efﬁcacy of plant sterol/
stanol consumption (2e3 g/day) is maintained on top of statin
therapy.
6.1.2. Ezetimibe
As the lipid-lowering mechanism of ezetimibe is mediated by
inhibition of intestinal cholesterol absorption, ezetimibe could be
considered a competitor of dietary plant sterols/stanols at the
molecular level. Importantly, however, the targets differ; ezetimibe
blocks the NPC1L1 transporter, while plant sterols/stanols displace
cholesterol from intestinal micelles. Moreover, as NPC1L1 is also the
entry gate for dietary plant sterols/stanols into the body, ezetimibe-
mediated inhibition of this mechanism should both enhance their
effects in the lumen of the intestine, and also reduce their plasma
Box 4
Consensus panel recommendations
 Daily consumption of foods with added plant sterols and/
or plant stanols in amounts of up to 2 g/day is equally
effective in lowering plasma atherogenic LDL-C levels by
up to 10%, and thus may be considered as an adjunct to
lifestyle in subjects at all levels of CV risk. At higher daily
intakes (9 g/day), the effects of plant stanols appear more
pronounced, but additional studies are needed to confirm
these results and examine safety at higher doses.
 Plant sterols and plant stanols can be efficaciously com-
binedwith statins. Very limited data suggest plant sterols/
stanolsmay also lower LDL-C levels in combinationwith a
fibrate or ezetimibe. In this way, the potential for attain-
ment of LDL-C goals as a function of overall CV risk can be
enhanced.
 Enhanced consumption of plant sterols and plant stanols
may be considered as an adjunct to lifestyle and dietary
approaches for modestly reducing elevated plasma tri-
glyceride levels, especially when levels are elevated
before treatment. This needs further study in appropriate
populations with elevated triglycerides.
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date, there was a signiﬁcant incremental reduction in intestinal
cholesterol absorption during administration of ezetimibe plus
plant sterols (2 g/day) associated with a signiﬁcant 8% reduction in
LDL-C compared to ezetimibe alone [153].
6.1.3. Other combination lipid therapy
The relevance of other combination therapies merits consider-
ation, especially from the perspective of comprehensive lipid con-
trol in cardiometabolic disease. Clinical studies show a trend for an
additive effect on LDL-C levels when foods enriched with plant
sterols/stanols are consumed with a ﬁbrate [154,155]. Given that
N  3 fatty acids have a small effect on cholesterol metabolism and
mainly inﬂuence triglyceride levels, consumption of plant sterols/
stanols and N  3 fatty acids may exert a complementary beneﬁcial
effect on the lipid proﬁle. Indeed, both are recommended asFig. 4. Addition of functional foods with plant sterols/stanols, as a component of lifestyle
mediate or low global cardiovascular risk who do not qualify for pharmacotherapy (as ind
Dyslipidaemia [56]. Equally, foods with added plant sterols/stanols may be considered in the
indicated by blue shading). Adapted from Reiner et al. (2011) [56].components of a healthy diet for prevention of CVD [56,156].
Currently there are insufﬁcient data regarding the lipid-lowering
efﬁcacy of a combination of bile acid sequestrants and dietary
plant sterols/stanols. However, as bile acid sequestrants interact
with lipophilic substances, it is likely that such a combination will
interfere with intestinal sterol/stanol absorption. Additionally, di-
etary plant sterols, but not plant stanols, suppressed bile acid
synthesis, probably altering bile acid sequestrant-mediated
cholesterol-lowering efﬁcacy [157].
In conclusion, the 10% reduction in serum LDL-C concentrations
typical of consumption of foods with added plant sterols/stanols at
doses of approximately 2 g/day, persists on top of the effect of
statins. Limited data suggest an additive effect of plant sterols/
stanols with ezetimibe and ﬁbrates.
6.2. Postprandial lipaemia
Since foods with added plant sterols/stanols reduce cholesterol
absorption, they might also reduce the production of intestinally-
derived chylomicrons and chylomicron remnants. The few studies
that have been conducted, using either a single standardised meal
or day-long measures of plasma triglycerides, have not shown any
effect of either acute or chronic plant sterol/stanol intake on post-
prandial triglycerides [150,158,159]. Where measured, levels of
postprandial plant sterols/stanols were variable [158,159]. Inter-
estingly, consumption of plant sterols esteriﬁed with ﬁsh oil for one
month resulted in lower postprandial triglyceride levels than ﬁsh
oils alone [160]. Overall, the limited data examining the potential
lowering of postprandial triglyceride excursions do not show sig-
niﬁcant effects, which might relate to low levels of baseline tri-
glycerides in subjects in these studies.
7. EAS consensus panel recommendations
Currently, foods with added plant sterols/stanols may be
considered in individuals with high cholesterol levels but equally in
thosewith intermediate or lowglobal CV risk who do not qualify for
pharmacotherapy [56]. On the basis of critical appraisal of the ev-
idence base above, this EAS Consensus Panel therefore considers
that there is a place for these products, in conjunction with otherintervention, may have potential value in individuals with high LDL-C levels at inter-
icated by pink shading), in line with the joint ESC/EAS Guidelines for Management of
context of lifestyle intervention in subjects at high or very high cardiovascular risk (as
Table 2
Comparison of the cost of foods with and without added plant sterols. Data based on
a strategic analysis of the European market (Frost & Sullivan Research Service,
London, UK, 2005) [163].
Product type Cost per kg (UK sterling) Incremental
cost ratioa
Foods with added
plant sterols
Foods without added
plant sterols
Spreads 7.46e7.98 1.80 4.14e4.43
Health drinks 4.95e8.10 2.20 2.25e3.68
Yoghurt 2.80e4.00 2.10 1.33e1.90
a Ratio of cost of foods with added plant sterols to cost of foods without plant
sterols.
Box 6
Health economic evaluation of consumption of foods with added
plant sterols and/or plant stanols
Nutrition economics follows a 4-step process in order to
compute the health and economic impact of penetration of
the market place of foods with added plant sterols/stanols.
To adopt the 4-step cost-of-illness approach:
 Determine a success rate for adoption of foods with
added plant sterols/stanols across the target population
 Evaluate the extent of LDL-C reduction due to consump-
tion of foods with added plant sterols/stanols
 Assess the decrease in coronary heart disease (CHD)
prevalence due to the estimated reduction in plasma LDL-
C levels
 Estimate the healthcare savings resulting from the
reduction in CHD prevalence
This multistep approach can be applied with a range of
inputted values for the 4 steps above, ranging from opti-
mistic to pessimistic.
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with statins or other agents who do not achieve LDL-C targets, or in
those with statin intolerance (see Box 4 and Fig. 4). Finally, given
the increasing importance of early preventive strategies in hyper-
cholesterolaemia [6], the potential for inclusion of plant sterol- or
plant stanol -enriched foods in the diet of adults and children (>6
years) with FH, as an adjunct to lifestyle and pharmacotherapy, may
be considered. We base these recommendations on the proven
ability of plant sterols/stanols to lower plasma LDL-C levels in the
absence or presence of concomitant statin therapy, and equally on
evidence that they reduce plaque size in atherosclerosis-prone
animal models. We understand that, in the absence of CVD
outcome data from randomised clinical trials, the evidence for use
of plant sterols/stanols is incomplete.
Healthcare professionals should take into account the level of
overall CV risk of patients, and their preferences. In addition, theBox 5
Unresolved questions
 Does inter-individual variability occur in the cholesterol-
lowering efficacy of plant sterols/stanols, i.e. is it
possible to identify hyper- versus hypo-responders? If so,
is it also possible to overcome lack of or poor respon-
siveness with higher plant sterol/stanol intake?
 Do plant sterols/stanols affect lipoproteins beyond LDL-C,
i.e. atherogenic triglyceride-rich lipoproteins and their
remnants, LDL and HDL subfractions, and lipoprotein(a)?
 Do plant sterols/stanols reduce the potential atheroge-
nicity of postprandial lipid and lipoproteins, especially in
subjects with cardiometabolic disease such as type 2
diabetes?
 How do plant sterols/stanols affect lipoprotein meta-
bolism in specific populations, for instance in patients
with the metabolic syndrome or type 2 diabetes mellitus
who exhibit an atherogenic lipoprotein phenotype?
 How do plant sterols affect cellular lipid homeostasis?
 How do plant sterols affect the function of cells involved
in the development of atherosclerosis, such as endothe-
lial cells, monocytes and macrophages under resting and
‘activated’ conditions in vitro, ex vivo and in vivo?
 Do plant sterols/stanols have significant effects on
biochemical surrogate markers of atherosclerosis
including coagulation, platelet aggregation, oxidant
stress, and subclinical inflammation?
 Is consumption of foods with added plant sterols/stanols
(2 g/day), as part of a healthy diet, associated with clinical
outcomes benefits? Given that large randomised out-
comes studies in low to moderate risk subjects are not
practically feasible, can sufficiently powered, randomised
controlled studies show significant effects of plant sterols
and/or stanols on morphological and functional (e.g.
endothelial function) surrogate markers of arterial
phenotype and/or atherosclerosis?cost of these products is relevant as there appears to be a signiﬁcant
relationship between socioeconomic level and the proﬁle of con-
sumption of food products [161,162]. Based on UK data, it is evident
that the cost/kg of food products with added plant sterols can range
from 1.3-fold to up to 4-fold higher than that of their conventional
counterparts (Table 2) [163]. Thus, cost may potentially constitute a
deterrent to the regular purchase of these products, especially
among less afﬂuent, higher-risk groups. Indeed, this is supported by
recent analyses from the Predi-Med study in Spain [164], which
suggest that economic difﬁculties in Southern Europe may have
had a detrimental effect on adoption of favourable dietary behav-
iours, including reduced adherence to the Mediterranean diet.
Further studies are needed to address unresolved questions
highlighted in this appraisal (see Box 5). Key priorities include (i)
evaluation of the effects of plant sterols/stanols in patients with
metabolic syndrome; (ii) Mendelian randomisation studies to
investigate the effects of plant sterols/stanols on clinical outcomes;
and (iii) evaluation of long-term safety and effects on clinical out-
comes in registries. Finally, although this EAS Consensus Panel did
not ﬁnd evidence for any health risk associated with consumption
of these functional foods, the Panel recognises the lack of outcomes
data showing clinical beneﬁt. Given practical constraints, and the
inability to differentiate LDL-C lowering effects of concomitant
pharmacotherapeutic and dietary approaches in polymedicated
patients, health economic modelling (see Box 6) may offer a
feasible approach to investigate whether wider use of these func-
tional foods has the potential for healthcare savings due to reduc-
tion in CVD prevalence. On the other hand, the EAS Consensus
Panel would clearly welcome, and applaud, efforts by the food in-
dustry to plan and conduct a well-designed and adequately pow-
ered study of the effects of plant sterol/stanol-supplemented foods
on CVD outcomes.
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